Clinical Trial

Identification of MPN-specific Antigens and Anti-MPN TCRs in Myeloproliferative Neoplasm

Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this observational study is to learn how the immune system responds to myeloproliferative neoplasms (MPN) in adults with known or suspected MPN. Researchers also want to identify immune cells that could help develop future immune-based treatments for MPN. The main questions it aims to answer are: * Are there T cells in the bone marrow that can recognize MPN cells? * Which targets (antigens) on MPN cells are recognized by these immune cells? * Can researchers identify T cell receptors (TCRs) that may be used in future TCR-based therapies? Researchers will study samples from adults with polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), post-PMF, or unclassifiable MPN. Samples from healthy donors without blood disorders will also be included for comparison. By providing blood and bone marrow samples, participants will: * Allow researchers to study immune cells and genetic material from these samples * Allow researchers to perform laboratory tests to study how immune cells recognize MPN cells Researchers will use laboratory methods such as genetic sequencing, cell analysis, and cell culture experiments to better understand immune responses in MPN. Participants will not receive direct medical benefit from this study. The results may help researchers better understand MPN and support the future development of immune-based therapies.
Trial Details
NCT Number NCT07590986
Lead Sponsor Université Catholique de Louvain
Conditions Myeloproliferative Neoplasm (MPN), Polycytemia Vera, Essential Thrombocythemia (ET), Primary Myelofibrosis (PMF)
Enrollment 150 participants
Start Date 2026-05
Primary Completion 2036-12 (estimated)
Study Completion 2037-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-15